Darborn
☆    

Taiwan,
2024-12-10 12:04
(64 d 22:58 ago)

Posting: # 24313
Views: 581
 

 Questions about "sequence effect" mentioned in a FDA PSG [General Sta­tis­tics]

Dear everyone,

I have questions about the FDA PSG of conjugated estrogen tablet. The screenshot is too large to upload, so I will quote the original texts here, and a link to original file. It's said:

"for the BE study under fasting condition, A replicate study design (TRTR and RTRT) is recommended to distinguish between unequal sequence and carryover effects in the single-dose fasting studies.The use of these two sequences (TRTR and RTRT) is the best design for balancing and minimizing bias should there be an unequal carryover effect in the study. A non-replicate (two-way crossover) study design may be conducted in lieu of the replicate study design, but the appearance of a statistically significant sequence effect may cast doubt on the conclusion of bioequivalence for the product."

My questions are:
1. Why FDA proposed this recommendation on using replicate design, is it to tell if the unequal sequence or carryover effects exist?
2. I check one of the previously conducted project which also use estrone (endogenous) as the analytes, and it does show significant sequence effect in ANOVA (P=0.01). This is unusual to other non-endogenous analytes as subjects are randomised to each arms. Is there any possible explanation?
3. Why FDA mentioned the appearance of a significant sequence effect will cast doubt on the conclusion of bioequivalence? :confused:

Sincerely
Darborn
UA Flag
Activity
 Admin contact
23,380 posts in 4,914 threads, 1,661 registered users;
32 visitors (0 registered, 32 guests [including 5 identified bots]).
Forum time: 11:03 CET (Europe/Vienna)

Everything is trivial, if you know the answer.    Thomas Jaki

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5